WO2004101615A3 - Especes de polypeptides secretes associes aux troubles cardio-vasculaires - Google Patents

Especes de polypeptides secretes associes aux troubles cardio-vasculaires Download PDF

Info

Publication number
WO2004101615A3
WO2004101615A3 PCT/EP2004/005195 EP2004005195W WO2004101615A3 WO 2004101615 A3 WO2004101615 A3 WO 2004101615A3 EP 2004005195 W EP2004005195 W EP 2004005195W WO 2004101615 A3 WO2004101615 A3 WO 2004101615A3
Authority
WO
WIPO (PCT)
Prior art keywords
cardiovascular disorders
secreted polypeptide
species associated
polypeptide species
polypeptides
Prior art date
Application number
PCT/EP2004/005195
Other languages
English (en)
Other versions
WO2004101615A2 (fr
Inventor
Lydie Bougueleret
Eve Mahe
Original Assignee
Genova Ltd
Novartis Pharma Gmbh
Lydie Bougueleret
Eve Mahe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genova Ltd, Novartis Pharma Gmbh, Lydie Bougueleret, Eve Mahe filed Critical Genova Ltd
Priority to EP04732961A priority Critical patent/EP1626986A2/fr
Publication of WO2004101615A2 publication Critical patent/WO2004101615A2/fr
Publication of WO2004101615A3 publication Critical patent/WO2004101615A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait à des polypeptides humains sécrétés circulant à un niveau accru dans la plasma de patients atteints de troubles cardio-vasculaires. L'invention a également trait à des procédés d'utilisation de compositions comprenant les polypeptides, des polynucléotides codant pour ces polypeptides, et des anticorps spécifiques pour ces polypeptides, pour le diagnostic, le pronostic, et le traitement de troubles cardio-vasculaires.
PCT/EP2004/005195 2003-05-16 2004-05-14 Especes de polypeptides secretes associes aux troubles cardio-vasculaires WO2004101615A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04732961A EP1626986A2 (fr) 2003-05-16 2004-05-14 Especes de polypeptides secretes associes aux troubles cardio-vasculaires

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47106103P 2003-05-16 2003-05-16
US60/471,061 2003-05-16

Publications (2)

Publication Number Publication Date
WO2004101615A2 WO2004101615A2 (fr) 2004-11-25
WO2004101615A3 true WO2004101615A3 (fr) 2005-01-20

Family

ID=33452426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005195 WO2004101615A2 (fr) 2003-05-16 2004-05-14 Especes de polypeptides secretes associes aux troubles cardio-vasculaires

Country Status (2)

Country Link
EP (1) EP1626986A2 (fr)
WO (1) WO2004101615A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10781253B2 (en) 2017-05-24 2020-09-22 Ngm Biopharmaceuticals, Inc. LEAP2 binding agents and compositions thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1104808A1 (fr) * 1999-08-05 2001-06-06 Genset ESTs et leurs protéines codées humaines
US20020137700A1 (en) * 1995-02-10 2002-09-26 Dean A. Falb Compositions and methods for the treatment and diagnosis of cardiovascular disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137700A1 (en) * 1995-02-10 2002-09-26 Dean A. Falb Compositions and methods for the treatment and diagnosis of cardiovascular disease
EP1104808A1 (fr) * 1999-08-05 2001-06-06 Genset ESTs et leurs protéines codées humaines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EPOP 15 January 2004 (2004-01-15), "Sequence 5204 from patent EP1104808", XP002297080, retrieved from EBI Database accession no. AX974401 *
KRAUSE ALEXANDER ET AL: "Isolation and biochemical characterization of LEAP-2, a novel blood peptide expressed in the liver.", PROTEIN SCIENCE, vol. 12, no. 1, January 2003 (2003-01-01), pages 143 - 152, XP002297079, ISSN: 0961-8368 *

Also Published As

Publication number Publication date
EP1626986A2 (fr) 2006-02-22
WO2004101615A2 (fr) 2004-11-25

Similar Documents

Publication Publication Date Title
WO2003101401A3 (fr) Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas
WO2004098377A3 (fr) Procedes et compositions pour le diagnostic et la therapie de troubles lies a la parkine
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2004022580A3 (fr) Peptides bh3 et leur methode d'utilisation
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2002060317A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
WO2002080754A3 (fr) Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
WO2002074156A3 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
MXPA03008739A (es) Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2004002431A3 (fr) Anticorps humanises diriges contre le recepteur de la lymphotoxine beta
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
WO2005030793A3 (fr) Anticorps se liant aux cxcr3 humains
WO2005014635A3 (fr) Especes de polypeptides secretes reduites dans les affections cardio-vasculaires
WO2005015206A3 (fr) Espece de polypeptides secretes associee aux troubles cardiovasculaires
WO2003037267A8 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
WO2006024958A3 (fr) Compositions cannabinoides et procedes d'utilisation correspondants
WO2005058251A3 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
WO2004106941A3 (fr) Especes de polypeptides secretes associees a des troubles cardio-vasculaires
WO2004047757A3 (fr) Diagnostic et traitement des cancers hematopoietiques
WO2004090551A3 (fr) Especes de polypeptides secretes associees a des troubles cardio-vasculaires
WO2005101000A3 (fr) Superagonistes de l'hormone glycoproteine humaine et utilisations
WO2004083241A3 (fr) Proteines interagissant avec btc et utilisation de ces proteines
WO2004101615A3 (fr) Especes de polypeptides secretes associes aux troubles cardio-vasculaires
WO2005003781A3 (fr) Especes de polypeptides secretes associes a des troubles cardiovasculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004732961

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006529821

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004732961

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004732961

Country of ref document: EP